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Abstract
Objective: The pathogenesis of sporadic idiopathic hypoparathyroidism is unclear. The calcium sensing
receptor (CaSR) plays a pivotal role in extracellular calcium homeostasis and is the candidate auto-
antigen in hypoparathyroidism associated with autoimmune polyglandular endocrinopathy syn-
drome. We therefore looked for antibodies (Ab) against the CaSR in patients with sporadic
idiopathic hypoparathyroidism and their association, if any, with the major histocompatibility com-
plex (MHC) class II human leukocyte antigen (HLA)-DR haplotypes.
Methods: The subjects included 51 patients with sporadic idiopathic hypoparathyroidism and 45
healthy controls. Investigations included computerised tomography, serum calcium, phosphorus,
thyroxine, TSH, cortisol, intact parathyroid hormone (iPTH), ACTH and thyroid peroxidase (TPO)
and adrenal antibodies. The CaSRAb were assayed in patients’ sera by Western blot. Genotyping of
the HLA-DR locus was performed using PCR and sequence-specific oligonucleotide probes.
Results: Intracranial calcification and cataract were present in 76.5% and 41.1% of the patients
respectively and 62.7% had convulsions. Autoantibodies against the 168 kDa CaSR protein were
demonstrated in the serum of 49.0% of the patients and in 13.3% of the controls (P , 0.001).
Pre-incubating serum samples from the CaSRAb-positive patients with parathyroid membrane pro-
duced a 90% decrease in the band intensity. HLA-DRB1*01 and DRB1*09 alleles were significantly
associated with idiopathic hypoparathyroidism (relative risk of 7.8, P ¼ 0.001). The frequency of
HLA-DRB1*09 and DRB1*10 alleles tended to be higher in patients positive for the CaSRAb. There
was no significant difference in the frequency of occurrence of convulsions, cataract, intracranial cal-
cification, calcium:phosphorus ratio, and iPTH levels between patients with and without CaSRAb.
Conclusion: 49.0% of the patients studied had serological evidence of organ-specific autoimmunity
against the CaSR protein. The occurrence of CaSRAb and the HLA-DR associations imply an auto-
immune component to the disease, but the primary role of the CaSRAb in the pathogenesis of the
disease needs to be assessed further.
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Introduction
Idiopathic hypoparathyroidism is a heterogeneous
group of disorders clinically characterised by the pre-
sence of tetany, cataract and basal ganglia calcification
in association with hypocalcaemia, hyperphosphatae-
mia and low or inappropriately normal serum intact
parathyroid hormone (iPTH) (1–5). The pathogenesis
of sporadic idiopathic hypoparathyroidism has not yet
been explained. In 1966, Blizzard et al. using indirect
immunofluorescence, had reported the presence of
parathyroid autoantibodies in patients with idiopathic
hypoparathyroidism, but the organ-specific nature of
these antibodies has been a subject of controversy
(6–9). Recently, the calcium sensing receptor (CaSR),
which is a G-protein-coupled receptor, has been
shown to play a pivotal role in the maintenance of
the extracellular calcium homeostasis, which it does
by sensing the circulating calcium levels and regulating
the PTH synthesis and release (10 –13). Li et al. have
reported the presence of autoantibodies against the
CaSR among patients with hypoparathyroidism, in
the majority of whom it was associated with the type
1 autoimmune polyglandular syndrome (APS-1) (14).
However, to our knowledge there is no report that
has investigated patients with sporadic idiopathic hypo-
parathyroidism for the presence of similar autoanti-
bodies. Therefore, we studied the prevalence of CaSR
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autoantibodies (CaSRAb) in a group of patients with
sporadic idiopathic hypoparathyroidism without associ-
ated APS-1 and examined their association with the
major histocompatibility complex (MHC) class II
human leukocyte antigen (HLA)-DR and with the clini-
cal and biochemical indices of the disease.
Subjects and methods
Subjects
The subjects included 51 consecutive patients with
hypoparathyroidism (29 males, 22 females) who
attended the Endocrine Clinic at the All India Institute
of Medical Sciences (AIIMS), New Delhi, from 1998
to 2002. Their mean age at presentation was 33.1^
12.8 years and the mean duration of their illness was
7.0^8.4 years. The diagnosis of idiopathic hypopar-
athyroidism was based on the presence of hypocalcae-
mia and hyperphosphataemia in association with an
inappropriately normal or subnormal level of serum
iPTH. Patients with post-surgical hypoparathyroidism
were excluded. None of the patients had a family his-
tory suggestive of hypoparathyroidism or adrenal insuf-
ficiency or clinical features of mucocutaneous
candidiasis. The type 1 autoimmune polyglandular
syndrome was excluded by demonstrating a normal
adrenocorticotrophin (ACTH) value in all the 38 of
51 patients in whom fresh plasma samples could be
obtained for ACTH assay. The 0800 h serum cortisol
was also normal in all the subjects and there were no
adrenal cortical autoantibodies observed using the
indirect immunofluorescence technique described ear-
lier (15). Six of the 51 patients (11.7%; 5 females and
1 male) had coexistent autoimmune disorders as evi-
denced by overt hypothyroidism in three, type 1 dia-
betes mellitus in one, alopecia areata with thyroid
peroxidase antibody (TPOAb) positivity in one and
TPOAb positivity alone in one. The study was approved
by the Research and Ethics Committee of the AIIMS and
written informed consent for participation was
obtained from all the subjects. Clinical symptoms,
including the duration of the illness and the presence
of tetany, convulsions, and cataract were noted. Non-
contrast computerised tomography of the brain was
carried out for intracranial calcification. Details of
one patient with reversible hypocalcaemic peripheral
neuropathy have been published earlier (16). A basal
blood sample was drawn after an overnight fast
(0800 h) for the estimation of serum calcium and
phosphorus and for the assay of iPTH (DiaSorin, Inc.,
Stillwater, MN, USA), total thyroxine (T4), thyrotrophin
(TSH) (Medicorp Inc., Montreal, Quebec, Canada),
cortisol (Immunotech, Marseille, France) and TPOAb
(Immunotech, Prague, Czech Republic), plasma ACTH
(DiaSorin, Minnesota, USA), as well as for CaSRAb
assays. Serum calcium and phosphorus levels were
measured using the standard techniques used in our
laboratory (17). All the samples were assayed for
hormones in a single batch. The controls included
45 healthy subjects (26 males, 19 females, mean
age 42^15 years). The normal range for the basal
hormone values were as follows: serum T4 ¼ 52–
167 nmol/l, TSH ¼ 0.3 –4.0 mU/l, cortisol ¼ 260 –
720 nmol/l, iPTH ¼ 13–54 ng/l, ACTH ¼ 1.3 –12.4
pmol/l. Intra-assay coefficients of variation ranged
from 4% to 8% for the measurement of these hor-
mones. As specified by the manufacturers of the
TPOAb-RIA kit, a serum TPOAb titre .100 IU/ml
was considered positive.
Western blot for the CaSRAb
The presence of antibodies against the calcium sensing
receptor was determined using Western blot analysis
(11, 18). Briefly, parathyroid adenoma tissues were
obtained at surgery from patients with primary hyper-
parathyroidism who underwent parathyroidectomy.
The tissues were snap frozen in liquid N2 and were hom-
ogenised in a glass homogeniser with a teflon pestle in
ice-cold lysis buffer in a 1:2 ratio by volume of sample
to lysis buffer (50 mmol/l Tris –HCl (pH 7.4);
0.25 mol/l sucrose; 1 mmol/l EGTA, EDTA, PMFS and
10mg/ml aprotonin, leupeptin and pepstatin (USB, Cle-
veland, OH, USA)). The nuclei and cell debris were pel-
leted by centrifugation at 800 £ g and the supernatant
then recentrifuged at 15 000 £ g to remove the mito-
chondrial fraction. The supernatant was finally sedi-
mented by centrifugation at 45 000 £ g for 1 h, and
the pellet suspended in 2 ml 1% Triton X-100 lysis
buffer. All the centrifugations were carried out at 4 8C.
The protein content of the solubilised membrane frac-
tion was estimated using Bradford’s reagent and the
readings taken at 595 nm (Shimadzu, UV160).
Parathyroid adenomas have been reported to show a
variable, often consistent reduction in the CaSR
expression (19). Therefore, in this study we used only
those parathyroid adenoma tissues whose cell mem-
branes showed a relatively high level of expression of
the CaSR for screening the patients’ sera for the
CaSRAb. This level of expression of the CaSR in the
different adenoma membranes was assessed by first
staining all our membrane preparations using a com-
mercially available anti-calcium sensing receptor anti-
body on Western blot (PA1-934, Affinity BioReagents,
Inc., Golden, CO, USA). Only those membrane prep-
arations which displayed a CaSR protein band of good
intensity on Western blot analysis were subsequently
utilised. The membrane fractions thus prepared were
made into aliquots of 100ml each (containing 2mg/ml
protein) and were stored at 220 8C until used. For
assay, one aliquot of the fraction prepared as described
above was mixed in a ratio of 1:5 with 5 £ Laemmli
buffer (0.32 Tris pH 6.8), 5% (w/v) SDS, 25% (v/v) gly-
cerol, 0.1% (w/v) bromophenol blue, 143 mmol/l
b-mercaptoethanol (Sigma, St Louis, MO, USA), and
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20mg of the protein were loaded in each well for electro-
phoresis without prior boiling. The proteins were frac-
tionated using SDS-PAGE mini gels (8 £ 7 cm with 5%
resolving and 4% stacking gels; Hoeffer, San
Francisco, CA, USA), transferred to PVDF membranes
and probed overnight with patients’ sera (1:50 dilution
with 1% Blotto/PBS) at 4 8C using a deca-probe incu-
bation manifold as described earlier (18). Anti-human
(1:1000 dilution) and anti-rabbit IgG conjugated
with horseradish peroxidase (1:500 dilution, DAKO,
Glostrup, Denmark) were used as second antibodies
(incubation time, 1.5 h) and 3-amino-9-ethylcarbizole
in 0.1 mol/l acetate buffer (pH 5.2) was used for optimal
colour development (AEC, DAKO, Carpinteria, CA, USA)
. In addition to the patients’ sera, each blot also included
4 lanes, 2 of these containing various positive controls,
pre-stained protein molecular weight markers, and a
negative control containing only 1% Blotto/PBS.
The various positive controls used included (i) a
commercially procured antibody against the CaSR
(PA1-934), (ii) a polyclonal, affinity-purified, anti-
CaSR antibody (code: 4637) raised in rabbits as
described earlier (19); both the above antibodies recog-
nised the 168 kDa as well as the 151 kDa isoforms of the
CaSR, and (iii) serum from a patient with hypoparathyr-
oidism which contained an antibody strongly positive
for only the 168 kDa CaSR protein. In order to minimise
the introduction of bias in the interpretation of results,
the blots were read independently by two investigators,
one of whom (E M B) was kept blind to the identity of the
samples (see Fig. 1).
Specificity of the CaSR antibody in the patients’ sera
was confirmed by doing neutralisation experiments
demonstrating the blocking of these antibodies using
antigens obtained from two different sources. (i) A
commercially available neutralizing peptide PEP-009,
against which the PA1-934 antibody had been
developed (Affinity BioReagents, Inc.); PEP-009 is a
16 amino acid synthetic peptide whose sequence is
derived from and is identical to the amino terminal
end of the rat CaSR protein (12 –27 amino acids:
A-L-A-W-H-S-S-A-Y-G-P-D-Q-R-A-Q). PEP-009 binds
and blocks the rat as well as the human CaSRAb
(20). (ii) A human parathyroid adenoma membrane
preparation which showed a good expression of the
CaSR on Western blot analysis as described above.
Serum samples obtained from two patients with hypo-
parathyroidism, which were most strongly positive for
autoantibodies against the 168 and 151 kDa CaSR
proteins were first serially diluted to determine the
lowest titre at which they tested positive for the
CaSRAb. The neutralisation of these antibodies was
then carried out by incubating the sera at this titre
with 30mg of the peptide PEP-009. The difference in
the integrated density value of the CaSRAb band
obtained in the presence and in the absence of the
PEP-009 peptide was measured by densitometry using
the image analyser software, Alphaease (ChemiImager
4400, Alpha Innotech Corp., San Leandro, CA, USA).
In order to demonstrate specific neutralisation of the
CaSRAb by the parathyroid adenoma membrane prep-
aration, 10ml serum from a patient whose serum was
strongly positive for CaSRAb were first incubated over-
night with an excess of the membrane protein on a
rocker at 4 8C, before carrying out the Western blot
analysis (200mg membrane protein in 500ml lysis
buffer). The neutralisation was assessed by densitome-
try as described above. Similar neutralisation exper-
iments to assess the specificity of the CaSRAb were
also performed using membrane preparations
(200mg each) from human liver and skeletal muscle
tissues obtained at autopsy (see Fig. 2B).
Western blot for CaSRAb using rat liver and
myocardial tissue, as well as human liver and
skeletal muscle membrane preparations
Since there are some reports in the literature showing
weak expression of the CaSR in the rat hepatocyte
and myocardial tissues (21, 22), we also examined
these tissues along with human liver and skeletal
muscle membranes, for expression of the calcium sen-
sing receptor and to investigate their ability to detect
the CaSRAb in the patients’ sera (see Fig. 3A and B).
The procedure adopted for extraction of membrane
preparations from the above-mentioned tissues was
essentially the same as described above for the para-
thyroid tissue membranes.
Genotyping for MHC class II, HLA-DR locus
In 36 of the 51 patients with hypoparathyroidism, DNA
was extracted from 10 ml blood using the standard
Figure 1 Immunoblotting of proteins from membranes prepared
from human parathyroid adenomas. A 5% SDS-PAGE Western
blot using parathyroid membrane protein (20mg protein/lane)
shows seropositivity against 168 and 151 kDa CaSR proteins by
CaSR-antibody-positive control serum (PA1-934) in lane 6 and
another positive control serum (4637 antibodies) in lane 7; nega-
tive control (1% blotto/PBS, blank) with no seropositivity against
the 168 and 151 kDa proteins is shown in lane 10. A patient with
hypoparathyroidism showing CaSRAb against 168 kDa in 1:200,
1:400 and 1:800 dilution (lanes 1, 2 and 3 respectively) and
28.4% neutralisation of seropositivity at a 1:800 dilution with neu-
tralizing peptide (NP) PEP-009 (lane 4), and a second patient with
hypoparathyroidism showing seropositivity in 1:50 dilution against
168 and 151 kDa proteins (lane 8) and 11.1% reduction of
151 kDa band positivity with NP-PEP-009 (lane 9) are also shown.
Lane 5, molecular weight (MW) markers.
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phenol –chloroform extraction technique (23). The
HLA-DR genotyping was carried out using PCR
(Applied Biosystem) followed by hybridisation with
sequence-specific oligonucleotide probes (PCR-SSOP).
Briefly, amplification of the second exon of the HLA-
DRB1 gene was performed using the primers described
earlier (24). The PCR products were run on 1% agarose
gels to confirm the amplification and were then dot
blotted on Hybond N(þ ) membranes (Amersham, Life
Sciences Inc., Chicago IL, USA) and UV cross linked.
The membranes with the dot blots were then hybridised
with 32P-labelled probes for DRB (1–18) generic. Differ-
ences in the frequency of the presence of specific HLA-
DR alleles in patients with hypoparathyroidism as a
group and when stratified according to CaSRAb positiv-
ity were compared with the data base already available
to us from 94 healthy controls drawn from the same
North Indian ethnic background (24).
Statistical analysis
Chi-square analysis was used to compare the frequency
of occurrence of CaSRAb positivity between the patient
and the control groups. The Chi-square test and the
Student’s t-test were used to compare the frequency
of occurrence and the mean of the different variables
respectively, between the group of patients with and
without CaSRAb. A P value of ,0.05 was considered
statistically significant. For HLA analysis, the P values
were calculated using Fisher’s exact test, and the
results obtained were corrected by multiplying by the
number of DR alleles tested. Relative risks and odds
ratios were calculated using Woolf ’s method with
Haldanes’s modification (25).
Results
A history of convulsions, cataract and intracranial cal-
cification on imaging was present in 32 (62.7%), 21
(41.1%) and 39 (76.5%) of the 51 patients respectively.
Subjects with intracranial calcification had a higher
frequency of occurrence of cataract when compared
with those without calcification (19/39, 48.7% vs
2/12, 17.7%, P ¼ 0.048). The mean duration of the ill-
ness was longer in patients who had intracranial calci-
fication or cataract as compared with patients without
these complications (9.0^9.5 years vs 2.4^4.1 years,
P ¼ 0.002 and 11.6^10.4 years vs 4.4^6.4 years,
P ¼ 0.01 respectively). On linear regression analysis
of the data in models where age of onset of symptoms,
duration of illness and serum calcium levels were
considered as independent variables, only the duration
of the illness explained the presence of the variations
observed in the frequency of occurrence of cataract
or basal ganglia calcification (dependent variables)
Figure 2 (A) Heterogeneity of the molecular weight of CaSR antigens. A 5% Western blot using parathyroid membrane protein (20mg
protein/lane) shows CaSRAb against 156 kDa antigen in a patient with idiopathic hypoparathyroidism in a serum dilution of 1:200 in
lane 4, and PA1-934 shows positivity against 156 and 136 kDa antigens in lane 2. Lane 1, blank and lane 3, molecular weight (MW)
markers. The membrane preparation used in this experiment belonged to a different patient undergoing parathyroid adenectomy than
that shown in Fig. 1. However, the sera in lane 4 of Fig. 2A, lane 2 of Fig. 2B and in lanes 1–3 of Fig. 1 were from the same patient.
(B) Specific neutralisation of the CaSRAb in a patient with idiopathic hypoparathyroidism with parathyroid membrane protein. A 5%
SDS-PAGE Western blot using various membrane protein preparations (20mg protein/lane) shows seropositivity against 156 kDa in a
patient with hypoparathyroidism (1:200 dilution, lane 2) and 90% neutralisation of CaSRAb band positivity after overnight preincubation
of the serum with parathyroid membrane (lane 3); only 16% and 28% neutralisation of CaSRAb positivity following preincubation of the
CaSRAb-positive sera with cell membrane preparations from human liver (LM, lane 4) and human skeletal muscle (SM, lane 5) is seen.
Lanes 1 and 6 are MW markers and blank (1% Blotto/PBS) respectively.
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respectively (15.4^45.7%, P , 0.01 and 16.7^40.2,
P , 0.002).
Western blot analysis demonstrated the presence of
antibody against the CaSR in 25 of the 51 (49.0%)
patients with hypoparathyroidism. The frequency of
occurrence of the CaSRAb among the 45 subjects with-
out any associated autoimmune endocrinopathy
(51.1%) was similar to that observed for the whole
group of 51 patients (49.0%). Twenty-one of the 25
patients showing CaSRAb were seropositive only for
the 168 kDa protein while four were positive for both
the 168 as well as the 151 kDa protein (Table 1,
Fig. 1). In contrast, only 6/45 (13.3%) of the controls
studied had autoantibodies against the 168 kDa CaSR
(patients vs controls P , 0.001). Following incubation
with an excess of the synthetic neutralising peptide,
PEP-009, whose sequence is identical to the amino
terminal end of the rat CaSR protein and which also
binds and blocks the human CaSRAb (20), there was
a 28.4% and 11.1% reduction in the integrated density
value (IDV) of the 168 kDa and 151 kDa bands respect-
ively (Fig. 1, lane 3 vs lane 4 and lane 8 vs lane 9).
Figure 3 (A) Immunoblot of membrane proteins (20mg protein/lane) prepared from rat liver (RL, lane 2), rat myocardial tissue (RM,
lane 3) and human parathyroid adenoma (HP, lanes 4 and 6). The 5% SDS-PAGE Western blot probed with the commercial CaSRAb-
positive control serum (PA1-934) shows the presence of the 168 kDa CaSR protein in lanes 3 (RM) and 4 (HP) and is also positive for
a 162 kDa antigen in lane 2 (RL). CaSRAb-positive serum (1:50 dilution) from a patient with hypoparathyroidism also shows reactivity
against the 168 kDa CaSR protein in lane 6 (HP). Lanes 1 and 5 are blank (1% Blotto/PBS) and molecular weight (MW) markers
respectively. (B) Immunoblot of membrane proteins (20mg protein/lane) prepared from rat liver (RL, lane 2), rat myocardial tissue (RM,
lane 3), human parathyroid adenoma (HP, lanes 4 and 10), human liver and skeletal muscle tissue obtained from two different
autopsies (HL a and b, lanes 6 and 8; HSM a and b, lanes 7 and 9). A 5% SDS-PAGE Western blot shows seropositivity against
168 kDa by PA1-934 CaSR antibody in lane 10. CaSRAb-positive serum (1:50 dilution) from a patient with hypoparathyroidism also
shows positivity against the 168 kDa CaSR protein in lanes 4 (HP), 7 and 9 (HSM a and b respectively, weekly positive). The same
patient’s serum showed no seropositivity against CaSR protein in lanes 2 (RL), 3 (RM) and in lanes 6 and 8 (HL a and b respectively).
Lanes 1 and 5 are blank (1% Blotto/PBS) and MW markers respectively.
Table 1 Calcium sensing receptor and thyroid peroxidase autoantibodies status and HLA-DR associations in patients with idiopathic
hypoparathyroidism and in healthy controls.
Parameters Patients Healthy controls P value
Overall CaSRAb positivity 25/51 (49.0%) 6/45 (13.3%) ,0.001
CaSRAb 168 kDa alone 21/51 (41.1%) 5/45 (11.1%) 0.0021
CaSRAb both 168 & 151 kDa 4/51 Nil 0.058
CaSRAb 151 kDa alone Nil Nil —
Thyroid peroxidase antibody positivity 3 (5.8%) 0 0.24
Frequency of HLA-DRB1*01 allele 4/36 (11.1%) 1/94 (1.1%) 0.020
Frequency of HLA-DRB1*09 allele 4/36 (11.1%) 2/94 (2.1%) 0.049
Frequency of HLA-DRB1*01þDRB1*09 alleles 8/36 (22.2%) 3/94 (3.2%) 0.0015
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Figure 2A and B displays the results of experiments
showing specific neutralisation of the CaSRAb in a
patient with idiopathic hypoparathyroidism. Following
preincubation of the serum with an excess of parathyr-
oid membrane proteins, the IDV of the CaSRAb band
was reduced by 90% on blot densitometry. In contrast,
the IDV of the CaSRAb band was reduced by only 16%
and 28% respectively when liver and skeletal muscle
membrane preparations were used. This reduction
in IDV could be explained by the relatively weak
expression of the CaSR in the human liver and skeletal
muscle preparations (Fig. 3A and B). In the parathyroid
adenoma membrane preparation used for neutralis-
ation experiments, both the commercial anti-calcium
sensing receptor antibody PA1-934, as well as the
CaSRAb from the patient with hypoparathyroidism,
reacted with the CaSR antigen protein at molecular
weights corresponding to 156 kDa and 136 kDa and
not with 168 kDa and 151 kDa, as observed in earlier
preparations (Fig. 2A and B).
Both the rat liver and the rat myocardial membrane
preparations showed CaSR expression as demonstrated
by their reactivity with the PA1-934 CaSR specific anti-
bodies (Fig. 3A). However, serum obtained from a
patient with hypoparathyroidism, which had reacted
strongly with the 168 kDa CaSR protein in a human
parathyroid membrane preparation, did not react
against the CaSR protein present in rat liver and myo-
cardial membranes, possibly indicating the species-
specific nature of the CaSRAb (Fig. 3B).
There was no significant difference in the frequency
of occurrence of the TPOAb positivity between the
patient and the control groups (Table 1). Table 2 gives
the details of the various other indices related to hypo-
parathyroidism, which were also examined in patients
with and without CaSRAb. Among the hypoparathyr-
oid patients, there were no significant differences
observed between the group of CaSRAb-positive and
CaSRAb-negative patients with regard to the male to
female ratio, frequency of occurrence of tetany, convul-
sions, cataract, basal ganglia calcification, mean serum
calcium, serum phosphorus or their ratios, serum iPTH
values or the frequency of presence of TPOAb. The six
subjects belonging to the control group who also
demonstrated serological evidence of CaSRAb were
asymptomatic and had no clinical or biochemical evi-
dence of hypoparathyroidism.
Of the 18 HLA-DRB alleles analysed, the frequency of
occurrence of HLA-DRB1*01 or DRB1*09 (n ¼ 4 each)
was significantly higher among the 36 patients with
hypoparathyroidism when compared with the fre-
quency of occurrence of the same alleles (n ¼ 1 and 2
respectively) in the 94 healthy controls studied who
were derived from the same ethnic background
(P ¼ 0.001, P corrected for 18 alleles tested ¼ 0.02)
with Haldanes’ corrected relative risk of 7.8. The fre-
quency of occurrence of the HLA-DRB1*09 or
DRB1*10 allele (n ¼ 4 each) was higher among
patients with hypoparathyroidism who were positive
for the CaSRAb as compared with those who were
negative for the antibody (n ¼ 1, P ¼ 0.02, corrected
P ¼ 0.36, odds ratio ¼ 5.2) (Table 1). However, there
was no significant difference in the frequency of occur-
rence of any of the specific alleles of the generic HLA-
DR when the 36 patients with hypoparathyroidism
were segregated on the basis of the presence or absence
of convulsions, cataract or intracranial calcification.
Discussion
In the present study, the incidence of intracranial calci-
fication, convulsions, and cataract as well as the male
to female ratio in the cohort of 51 patients with idio-
pathic hypoparathyroidism, were comparable to what
has been reported earlier in the literature (26 –29).
Table 2 Study variables in relation to calcium sensing receptor autoantibody status in patients with idiopathic hypoparathyroidism.
Parameters CaSRAb 1ve (n ¼ 25) CaSRAb –ve (n ¼ 26) P value
Sex (Male:Female) 15:10 14:12 0.65
Age (years) 31.9^12.4 34.3^13.5 0.50
Duration of symptoms (years) 8.3^9.3 6.2^7.7 0.38
BMI (kg/m2) 20.7^4.1 22.0^5.1 0.68
History of convulsions 19/24 (76.0%) 13/24 (50.0%) 0.054
History of tetany 19 (76.0%) 17 (65.4%) 0.40
Cataract 12 (48.0%) 9 (34.6%) 0.33
Serum calcium (mmol/l) 1.44^0.27 1.44^0.20 0.97
Serum inorganic phosphorus (mmol/l) 2.03^0.45 2.1^0.32 0.40
Intracranial calcification 20 (80%) 19 (73.0%) 0.61
Serum intact PTH (ng/l) 10.0^9.2 9.7^7.0 0.88
Thyroid peroxidase antibody positivity 2 (8.0%) Nil 0.99
Hypothyroidism Nil 3 (11.5%) 0.23
Frequency of HLA-DRB1*09 allele 4/19 (21.0%) 0/17 0.065
Frequency of HLA-DRB1*10 allele 4/19 (21.0%) 1/17 (5.8%) 0.20
Frequency of HLA-DRB1*09 þ DRB1*10 alleles 8/19 (42.1%) 1/17 (5.8%) 0.014
BMI, body mass index.
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The present study also demonstrated the coexistence of
intracranial calcification and cataract, both of which
were individually associated with a longer duration of
the illness. However, the duration of the illness could
explain the variation in the occurrence of intracranial
calcification and cataract in only 15–16% of the
patients. These findings suggest a role for other factors
in their aetiology.
In 1966, Blizzard et al. using indirect immunofluor-
escence had reported the presence of parathyroid
autoantibodies in 33% of patients with idiopathic hypo-
parathyroidism (6). However, Swana et al. (1977) and
Betterle et al. (1985) using similar techniques demon-
strated anti-mitochondrial antibodies staining the
mitochondria-rich oxyphil cells of the parathyroid
gland and suggested that these could be the cause of
the seropositivity observed in patients with idiopathic
hypoparathyroidism, which had been reported earlier
(8, 9). Using Western blot assays, Fattorossi et al.
(1988) first described the presence of the 200 kDa
and 130 kDa autoantigens in the parathyroid
endothelial/epithelial cells of six patients with
idiopathic hypoparathyroidism (30). Subsequently, Li
et al. in 1996 identified the CaSR as an autoantigen
and demonstrated antibodies against this receptor in
56% of 25 patients with hypoparathyroidism, 8 of
whom were adults with hypoparathyroidism and
coexisting thyroiditis and 17 were children with type
1 autoimmune polyglandular syndrome (14).
The inclusion of hypoparathyroidism among the
autoimmune endocrinopathies associated with the
autoimmune polyglandular syndrome, and the demon-
stration of CaSR autoantibodies in these patients
indirectly suggests that similar autoimmune mechan-
isms might be operative in subjects with idiopathic
hypoparathyroidism. Patients who have endocrinopa-
thies linked with the autoimmune polyglandular
syndrome often demonstrate a higher prevalence of
organ-specific autoantibodies and exhibit autoantigens
of a different type as compared with patients having
the same endocrinopathies occurring in isolation with-
out the polyglandular syndrome (31, 32). For example,
Uibo et al. (31) reported the presence of autoantibodies
against the cytochrome P450c17, P450scc and/or
P450c21 hydroxylases in 81% of their patients with
Addison’s disease associated with the autoimmune
polyglandular syndrome while, in contrast, only 25%
of the patients with isolated Addison’s disease demon-
strated these autoantibodies, which were found to be
directed exclusively against P450c21 hydroxylase
(31, 32). In the present study, the majority of patients
had sporadic idiopathic hypoparathyroidism without
coexisting autoimmune endocrinopathy (45/51) and
51.1% of them had serological evidence of autoanti-
bodies against the CaSR.
In the present study, six of the 45 healthy controls
(13.3%) also showed CaSR autoantibodies. Blizzard
et al. (1966) had also reported 6% of their controls to
be positive for parathyroid autoantibodies (6). On the
other hand, Li et al. did not detect CaSR autoantibodies
in any of the 22 healthy controls studied by them (14).
These variations observed in the prevalence of para-
thyroid autoantibodies among healthy controls may
be due to differences in the number of controls studied.
Interestingly, in the present study, none of the six con-
trols who were positive for CaSR autoantibodies showed
clinical or biochemical signs of hypoparathyroidism.
The CaSR protein can migrate to several different
positions on SDS PAGE depending upon variations in
the degree of its glycosylation or dimer formation (10,
12). Under non-reducing conditions, the 151 kDa
band represents the immature, high mannose, less gly-
cosylated form of the CaSR protein, and the band corre-
sponding to the 168 kDa protein represents the
monomeric, mature receptor which is fully glycosy-
lated. The N-linked glycosylation of the CaSR protein
is important for the normal expression of the receptor
on the cell surface (11 –13). The protein band analo-
gous to a molecular weight of .250 kDa represents
the dimer of the CaSR (12). Thus, in the present
study, all the 25 patients had autoantibodies demon-
strated against the 168 kDa CaSR autoantigen and
only 4 of them had autoantibodies against the
151 kDa protein. However, while conducting the neu-
tralisation experiment for the CaSRAb when we used
parathyroid adenoma membrane preparations obtained
from different patients, the commercial calcium sensing
receptor antibody PA1-934 as well as the CaSRAb from
the strongly positive patient’s sera reacted with proteins
corresponding to a CaSR molecular weight of 156 kDa
and 136 kDa instead of 168 kDa and 151 kDa as
observed earlier (Fig. 2B). This reactivity of the CaSR
autoantibody was reduced by 90% on incubation of
the serum with an excess of parathyroid membrane
protein, confirming that these autoantibodies were
CaSR-protein specific (Fig. 2A). However, incubation
of the serum samples with the 16 amino acid synthetic
analogue of the extracellular part of the CaSR (PEP-
009) resulted in only a 28.4% decline in reactivity of
CaSR antibody. The difference in the neutralisation of
the CaSRAb observed when using parathyroid mem-
brane preparation and PEP-009 peptide (extracellular
part of the CaSR) suggests that these patients with idio-
pathic hypoparathyroidism may have a heterogeneous
pool of autoantibodies with binding sites directed
against different epitopes of CaSR (Fig. 1). Further,
the CaSR autoantibody present in the serum of one of
the patients with hypoparathyroidism appeared to be
species specific, because although it had reacted
strongly with the CaSR antigen in the human parathy-
roid membrane preparations, the antibody failed to
react with the CaSR protein when membranes from
rat liver or myocardial tissues were used (Fig. 3B).
In the present group of hypoparathyroid patients
studied, we can only speculate whether the CaSR auto-
antibodies observed bring about the primary destruction
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of the parathyroid gland or whether these autoanti-
bodies mark the end stage of a disease process which
originally begins with damage to the parathyroid
gland mediated by the Th1 lymphocytes with conse-
quent activation of the local Th2 cells, leading to the
gradual development of autoantibodies, a pattern of
progression which may take place in predisposed indi-
viduals with specific class II haplotypes. Brandi et al.
have demonstrated antibody-dependent cytotoxicity
in cultured bovine parathyroid cells when exposed to
serum from patients with autoimmune hypoparathyr-
oidism and type 1 APS (3). Besides, Wortsman et al.
have demonstrated T lymphocyte activation with
increased natural killer cell activity but an absence of
B-cell activation in patients with adult onset idiopathic
hypoparathyroidism (2). Weak immunohistochemical
reactivity for both MHC class I and class II antigens
has been demonstrated in dispersed normal human
parathyroid cells (33). While we could demonstrate
HLA-DR associations in the whole cluster of patients
with idiopathic hypoparathyroidism, the CaSRAb
detected in the sera of these patients did not correlate
with either the clinical manifestations or the biochemi-
cal abnormalities of the disease. In diseases where auto-
antibodies have a primary role in pathogenesis, the
clinical and biochemical severity of the illness correlates
with the degree of seropositivity, for example in Graves’
disease and myasthenia gravis (34, 35). Thus, among
the patients in the present study the absence of any cor-
relation of the CaSRAb with the clinical or biochemical
manifestations of the disease may either represent an
epiphenomenon due to immune activation or might
involve antibody-dependent cell-mediated cytotoxicity.
Alternatively, the CaSRAb might lead to a decline in
the PTH release essentially by acting as an agonist for
binding to the CaSR that is naturally expressed on the
parathyroid cell membranes. However, such a phenom-
enon by itself would not bring about the parathyroid
gland atrophy and lymphocytic infiltration that have
been observed and reported at autopsy in a few patients
with idiopathic hypoparathyroidism (4). While the
above facts argue against a primary role and any func-
tional significance of the CaSRAb among patients with
idiopathic hypoparathyroidism, there is a recent report
of CaSR blocking autoantibodies described in patients
with a syndrome resembling familial hypocalciuric
hypercalcemia (36). However, in order to reveal the
pathogenetic mechanism(s) at work, further studies
need to be done in vitro to examine the possible role
of the CaSR autoantibody in altering the normal func-
tioning of the G-protein-mediated intracellular signal-
ling pathways used by this receptor, as well as an
analysis of the Th1 and Th2 cytokine profiles among
patients with idiopathic hypoparathyroidism. In the
present study, the hypoparathyroidism observed in
51% of patients in whom serological evidence of
CaSRAb could not be demonstrated would still be
referred to as ‘idiopathic hypoparathyroidism’. In this
group, the existence of autoimmunity to antigens
other than the CaSR or disappearance of the CaSRAb
positivity are possible alternatives. Moreover, in the pre-
sent cohort of patients, we also cannot rule out the
theoretical possibility of the existence of activating
mutations of the CaSR gene or altered cleavage of the
PTH signal peptide due to a mutation in the prepro-
PTH gene – both known causes of hypoparathyroidism.
However, genetic mutations involving the CaSR and
prepro-PTH gene have been reported among patients
with familial isolated hypoparathyroidism and not in
subjects with the sporadic form of hypoparathyroidism
of the type reported in the present study (37, 38).
Multiple target gland involvement is frequent among
patients with autoimmune endocrinopathies. In India,
among patients with type 1 diabetes mellitus with no
clinical and biochemical evidence of hypothyroidism,
the prevalence of concurrent thyroid autoimmunity is
26% (39). In the present study, while we could docu-
ment serological evidence of CaSRAb in half of the
patients with hypoparathyroidism, the observed fre-
quency of coexisting thyroid autoimmunity was only
9.8% which was not significantly different from that
observed among the controls. This would suggest that
patients with idiopathic hypoparathyroidism develop
autoimmunity to the thyroid gland only infrequently.
The autoimmune nature of hypoparathyroidism
warrants a study of its HLA associations. However,
there is no data on HLA-DR associations among
patients with idiopathic isolated hypoparathyroidism.
In the present study the occurrence of the HLA-
DRB1*01 or DRB1*09 alleles was significantly higher
among the hypoparathyroid patients, with a relative
risk of 7.8. Allelic variations were also demonstrated
in relation to their CaSRAb status, with the frequency
of HLA-DRB1*09 or DRB1*10 being higher in the
CaSRAb-positive patients with an odds ratio of 5.2.
However, the latter did not attain statistical signifi-
cance. No similar association in allelic variation was
observed when the patients were stratified on the
basis of presence or absence of complications such as
intracranial calcification or cataract. Further detailed
studies involving associations with HLA class 1 and
class II-DQB1, DQA1 and DPB1 alleles in the present
group of patients might reveal such associations.
To conclude, the present study documents serological
evidence of autoimmunity against a 168 kDa CaSR pro-
tein in almost half (49%) of a group of patients with
sporadic idiopathic hypoparathyroidism who were
investigated. The antibodies were demonstrable even
up to six years after the onset of the disease. While
CaSRAb seropositivity and HLA-DR associations sup-
port the autoimmune nature of the disease, the primary
role of the CaSRAb in the pathogenesis of the idiopathic
hypoparathyroidism needs to be further examined in
view of the fact that the CaSRAb positivity did not seg-
regate patients with regard to the frequency with which
they developed convulsions, cataract, intracranial
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ganglia calcification, abnormal phosphorus/calcium
ratio or any other clinical manifestations of the disease
studied.
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